Related Experiment Videos
Selective removal of circulating immune complexes from patient plasma
Siegfried Kunkel1, Manfred Holtz, Beatrice Grossjohann
1R&D Center of Bioengineering GmbH, Rostock/Teterow, Germany. kunkel@cob.bioeng.de
Artificial Organs
|March 7, 2002
Summary
Patient-specific immunoadsorbers (PsIA) effectively remove circulating immune complexes from plasma. These autologous systems show promise for treating autoimmune diseases like rheumatoid arthritis and lupus erythematosus.
Area of Science:
- Biomedical Engineering
- Immunology
- Analytical Chemistry
Background:
- Circulating immune complexes (CICs) play a role in autoimmune diseases.
- Current treatments may lack specificity or efficacy.
- Patient-specific immunoadsorbers (PsIA) offer a targeted approach.
Purpose of the Study:
- To demonstrate the principle and efficacy of patient-specific immunoadsorbers (PsIA).
- To evaluate the performance of PsIA in removing CICs from patient plasma.
- To compare PsIA performance with standard protein A adsorbers.
Main Methods:
- Model system studies (HSA/anti-HSA) for immobilization, stability, and leakage.
- Fast-performance liquid chromatography (FPLC) and batch adsorption experiments.
- Quantification of plasma IgG, total protein, C1q, and C3d CICs using autologous and heterologous PsIA and protein A adsorbers.
Main Results:
- Autologous PsIA systems demonstrated suitability for selective CIC removal.
- Binding capacities of protein A adsorbers and PsIA were determined.
- Analysis of plasma from patients with rheumatoid arthritis and systemic lupus erythematosus showed elevated CIC levels.
Conclusions:
- Autologous PsIA are effective for the selective removal of elevated CICs in autoimmune diseases.
- PsIA offer a promising therapeutic strategy for managing autoimmune conditions.
- Further research into PsIA optimization and clinical application is warranted.